First European CMT1A Patient Enrolled in PREMIER Trial

First European CMT1A Patient Enrolled in PREMIER Trial

299679

First European CMT1A Patient Enrolled in PREMIER Trial

Pharnext has enrolled the first patient in Europe for its Phase 3 clinical trial of PXT3003, an investigational therapy for Charcot-Marie-Tooth disease type 1A (CMT1A). The international PREMIER trial (NCT04762758) is already underway in the United States, where the first patient was dosed earlier this year. “We are delighted to see the ongoing progress in the enrollment of the PREMIER trial through the opening of the first European center in Marseille [France] according to plans,” Adrian…

You must be logged in to read/download the full post.